Case Report
From TTP to Glomerulonephritis: A Lifetime of Lupus

Fadi Kharouf, Sigal Shahar, Yoav Hershkovitz, Alaa Shaheen, Areej Bayatra, Asa Kessler, and Yuval Ishay

1Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel
2Rheumatology Unit, Hebrew University-Hadassah Medical Center, Jerusalem, Israel
3Gastroenterology Unit, Hebrew University-Hadassah Medical Center, Jerusalem, Israel

Correspondence should be addressed to Fadi Kharouf; fadikharouf@hotmail.com

Received 24 November 2020; Accepted 26 December 2020; Published 5 January 2021

1.Introduction
Systemic lupus erythematosus (SLE) is the prototypical systemic autoimmune disease, characterized by a wide spectrum of clinical manifestations, often exhibiting a relapsing-remitting course [1]. As treatment is based on immunosuppressive therapy, infections pose a major iatrogenic complication [2]. Here, we report a unique case of a middle-aged male, gradually presenting with a diverse constellation of systemic manifestations over a prolonged period. We discuss the clinical presentation, diagnostic implications, therapeutic decisions, and treatment complications.

2. Case Presentation
A 56-year-old male presented to the emergency department with a 2-month history of extreme weakness, fatigue, and anorexia. His past medical record was remarkable for a previous event of thrombotic thrombocytopenic purpura (TTP) 20 years earlier. He was then treated with plasmapheresis, aspirin, and corticosteroids, with complete recovery. 18 months thereafter, he was diagnosed with an unprovoked right leg deep vein thrombosis (DVT), for which no etiology was found. Noticeably, antiphospholipid antibodies (APLAs) were negative.

Similar constitutional symptoms had plagued the patient before. Several years prior to his current presentation, he was admitted for weakness and weight loss (30 kg over a few months). He then underwent a thorough investigation, including blood tests, whole-body computed tomography (CT), and positron emission tomography/CT (PET/CT). Diffuse hypermetabolic lymphadenopathy, involving axillary, abdominal, and retroperitoneal lymph nodes (LN), was seen. Excision biopsy of a pelvic LN (PN) and bone marrow (BM) biopsy were performed, both being unremarkable. Immune serologies sent at that time showed only a weakly positive antinuclear antibody (ANA). The differential diagnosis comprised a systemic infection, an indolent neoplastic process, and autoimmune lymphoproliferative syndrome (ALPS). None of these entities was proven however, leaving the patient undiagnosed despite regular follow-up. Thereafter, he spontaneously recovered, enjoying several uneventful years.

Upon the patient’s current admission, physical examination revealed mild bilateral leg edema and numerous
lichen-like skin lesions (see Figure 1). Recurrent fever spikes of up to 39°C were recorded, with otherwise normal vital signs. Blood tests were extremely abnormal, showing pancytopenia, hypoalbuminemia, high creatinine levels, and elevated inflammatory markers (see Table 1). While whole-body CT displayed no noteworthy findings, PET/CT demonstrated widespread hypermetabolic lymphadenopathy and diffusely increased BM uptake. BM and groin LN biopsies were performed, again being noncontributory. Peripheral blood flow cytometry, however, showed a high proportion (7%) of double-negative (DN) T cells (negative for both CD4+ and CD8+). Blood cultures and broad bacterial and viral serologies were negative. The patient’s urinalysis was significant for hematuria and proteinuria, and urine microscopy revealed red blood cell (RBC) casts, along with dysmorphic RBCs. 24-hour urine collection demonstrated nephrotic range proteinuria (3.9 g/d).

During this time, the patient’s clinical condition was one of the ongoing weakness, fatigue, and dyspnea. He also suffered from pleuritic chest pain and progressive, asymmetric leg edema. Further work-up directed at these complaints showed an extensive right leg DVT, elevated cardiac enzymes, and new-onset atrial fibrillation (AF). In addition, a small pericardial effusion was found on transesophageal echocardiography (TTE). Therapy with enoxaparin was started for his DVT and AF, and broad-spectrum antibiotic coverage was instituted for a suspected bacterial infection. Pericarditis was added to this ever-growing list of diagnoses.

Results of ANA and anti-double-stranded deoxyribonucleic acid (anti-dsDNA) antibody were reported at this stage, both being strongly positive, along with low complement levels (see Table 2). Notably, APLAs were negative. In light of the patient’s deteriorating renal function and active urinary sediment, kidney biopsy was performed.
Lupus nephritis stages 3 and 5 (focal proliferative and membranous glomerulonephritis, respectively) were present on pathology. Biopsy of the skin lesions demonstrated immune complex (lupus band) deposition and a lichen planus-like pathological picture. The patient was thus diagnosed with SLE and started on high-dose corticosteroid therapy, hydroxychloroquine, mycophenolate mofetil, and ramipril, with impressive clinical and laboratory improvement. After a 4-week hospital stay, he was eventually discharged for follow-up at the rheumatology and nephrology outpatient clinics.

Less than one month after discharge, the patient was readmitted due to a painful right calf ulcer, productive cough, and general weakness. Thorough work-up revealed significant cytomegalovirus (CMV) viremia (>925,000 copies/mL), with no signs of visceral involvement upon bronchoscopy, sigmoidoscopy, and ophthalmologic evaluation. The leg ulcer was attributed to postphlebitic syndrome, and biopsy of the ulcer was noncontributory. Cultures from both the ulcer and bronchoalveolar lavage fluid grew Pseudomonas aeruginosa, and therapy with ciprofloxacin was started. Besides, mycophenolate mofetil and prednisone doses were reduced in an attempt to minimize immunosuppression, and intravenous ganciclovir therapy was initiated. The lack of clear signs of end-organ involvement has made it difficult to define the required duration of ganciclovir treatment, and the CMV viremia was monitored instead. Following the gradual elimination of viremia, antiviral therapy was stopped. Diligent wound care, compression stockings, and antibiotic treatment allowed stepwise healing of the ulcer.

Three months later, the patient was again admitted for sudden-onset dysarthria and right-sided hemiparesis. Brain CT angiography showed left middle cerebral artery branch obstruction, consistent with an embolic etiology. An emergent thrombectomy was performed. TTE, transesophageal echocardiography (TEE), and carotid Doppler studies revealed no embolic source. Aspirin and high-dose statin were added, and the patient continued apixaban. Gradually, he was able to regain excellent functional capacity.

As of today, one year after his index presentation, the patient is well and suffers no residual neurologic deficits. His most recent labs, including blood counts, chemistry panels, complement levels, and urinalysis, are unremarkable. His proteinuria has declined to 170 mg/d, and CMV titers in blood are undetectable.

### 3. Discussion

Our patient was eventually diagnosed with SLE. Over 20 years, he presented with an assembly of disease manifestations, including hematologic, musculoskeletal, dermatologic, cardiac, and renal phenomena. Initially experiencing events of TTP and DVT, he went on to develop, over many years and in a relapsing-remitting manner, constitutional symptoms, arthralgia, lymphadenopathy, pancytopenia, skin lesions, pericarditis, and glomerulonephritis. Past immune serologies showed only a weakly positive ANA, with normal complement levels. The absence of classic lupus manifestations in the past obscured the diagnosis, and it was not until significant visceral involvement occurred many years thereafter, that the correct conclusions were drawn. In these days of extensive testing and follow-up, “the great pretender,” lupus, appears to present a lesser diagnostic dilemma than in the past. Atypical manifestations, combined with spontaneous disease remissions, may nonetheless obfuscate the clinical picture.

Constitutional symptoms, including fatigue, anorexia, fever, and weight loss, are commonly seen in patients with SLE. Fatigue is a frequent, sometimes disabling, disease symptom. Its etiology is multifactorial and includes chronic inflammation, cytokine dysregulation, side effect of medications, comorbidities, and hormonal imbalances [3]. Fever occurs in 42–86% of SLE patients [4]. Its work-up can be challenging, and the disease occasionally presents as fever of unknown origin (FUO) [5].
SLE is known to have myriad hematologic manifestations, many of which appeared in our case. Lymphadenopathy is a common, often unappreciated feature. LNs are usually soft and nontender and may fluctuate in size with disease exacerbations. Biopsy usually shows reactive hyperplasia [6]. 50% of patients with SLE develop anemia, usually due to chronic inflammation and iron deficiency, and less often due to autoimmune hemolysis [7]. White blood cell abnormalities are also common in lupus and include leukopenia, lymphopenia, and neutropenia [8]. Thrombocytopenia, when related to active disease, tends to be lower than 50,000/mm³ and usually necessitates aggressive therapy [9]. While TTP may be a rare manifestation of SLE, it is seldom the presenting feature [10]. Thrombosis, on the contrary, is a well-known finding in the disease and is multifactorial. Despite APLAs being the most important risk factor, 40% of SLE patients negative for these antibodies will still experience a thrombotic event. Other factors that contribute to thrombosis in lupus include inflammatory disease activity, medications, and traditional risk factors (including smoking, diabetes, and hypertension) [11]. Immunologically, it is noteworthy that SLE patients may have increased numbers of DN T cells in peripheral blood, probably driven by excessive T cell stimulation. These cells synthesize interleukins and can stimulate B cells, contributing to the pathogenesis of kidney damage, for instance [12].

Regarding cardiac involvement, SLE can affect any layer of the heart. Pericardial effusion secondary to pericarditis is the most common manifestation [13]. Valvular heart disease is also well known in SLE. Left-sided valvular thickening is the predominant finding, followed by valvular vegetations, regurgitation, and stenosis [14]. It is worth mentioning that, in Libman–Sacks endocarditis complicating SLE, the sterile valvular vegetations have a greater tendency to embolize than in infective endocarditis, thus predisposing to neurovascular disease, including ischemic stroke [15]. The latter is twice as common in SLE patients as compared to the general population. Contributing factors include embolic events, comorbidities (such as antiphospholipid syndrome and hypertension), systemic inflammation, and treatment complications [16]. AF, present in our case, is also known to be more common in SLE patients and is associated with increased mortality [17].

Skin disease is a well-characterized feature of lupus. Chronic cutaneous lupus includes a lupus-lichen overlap entity [18]. In the majority of patients with systemic disease, immunofluorescence reveals deposits at the dermal-epidermal junction in normal non-sun-exposed skin and at sites of cutaneous lesions, the so-called lupus band test [19].

Renal involvement remains one of the most devastating manifestations of SLE, with increased morbidity and mortality. Despite advances in management, 10% of the patients still progress to renal insufficiency and end-stage renal disease [20].

Complications of immunosuppression are also represented in our case. CMV viremia dominated the clinical picture, necessitating reduction of immunosuppression and institution of prolonged intravenous antiviral therapy. The heavy immunosuppressive regimens used in systemic autoimmune diseases are known to predispose to opportunistic infections. These remain the most frequent cause of hospitalization, morbidity, and mortality in SLE patients. More than half of the infections are viral, the most common being herpes zoster [2]. No guidelines in the field of rheumatology advise in favor of prophylactic therapy against CMV upon heavy immunosuppression, as opposed to the recommendations in patients undergoing BM transplantation. In cases of symptomatic CMV disease, treatment involves both the minimization of immunosuppression and the institution of antiviral therapy, typically with oral ganciclovir or intravenous ganciclovir [21]. Duration of intravenous therapy is usually guided by the target organ, lacking in our patient.

We believe our case is educational in several aspects. First, the patient showed a remarkable mixture of systemic manifestations (see Figure 2), varying in severity, pattern, and timing, with the eventual diagnosis being made two decades after his initial presentation. Secondly, despite appropriate therapy, he went on to develop complications of the disease and its treatment, including DVT, AF, CMV viremia, and stroke. Finally, the correct utilization of the therapeutic armamentarium and the proper implementation of urgent interventions yielded an excellent outcome.

Abbreviations

AF: Atrial fibrillation
ALPS: Autoimmune lymphoproliferative syndrome
ANA: Antinuclear antibody
Anti-dsDNA: Anti-double-stranded deoxyribonucleic acid
BM: Bone marrow
C: Complement
CMV: Cytomegalovirus
CT: Computed tomography
CRP: C-reactive protein
DN: Double negative
DVT: Deep vein thrombosis
RBC: Red blood cell
ESR: Erythrocyte sedimentation rate
FUO: Fever of unknown origin
LN: Lymph node
PET: Positron emission tomography
SLE: Systemic lupus erythematosus
TEE: Transesophageal echocardiography
TTE: Transthoracic echocardiography
TTP: Thrombotic thrombocytopenic purpura.

Data Availability

All data used to support our findings are included within the article, and any additional data will be provided by the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare that there are no conflicts of interest.
Acknowledgments

The authors thank Professor Y. Ilan and Doctor H. Peleg for their important contribution to the patient’s care.

References

[1] F. Tamirou, L. Arnaud, R. Talarico et al., “Systemic lupus erythematosus: state of the art on clinical practice guidelines,” RMD Open, vol. 4, no. 1, Article ID e000793, 2018.

[2] E. M. Ginzler and O. Dvorkina, Infections in Systemic Lupus Erythematosus, Lippincott, Williams & Wilkins, Philadelphia, PA, USA, 7th edition, 2006.

[3] S. Cleanthous, M. Tyagi, D. Isenberg, and S. Newman, “What do we know about self-reported fatigue in systemic lupus erythematosus?” Lupus, vol. 21, no. 5, pp. 465–476, 2012.

[4] J. Font, R. Cervera, M. Ramos-Casals et al., “Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center,” Seminars in Arthritis and Rheumatism, vol. 33, no. 4, pp. 217–230, 2004.

[5] B. A. Cunha, O. Lortholary, and C. B. Cunha, “Fever of unknown origin: a clinical approach,” American Journal of Medicine, vol. 128, no. 10, pp. 1138.e1–1138.e15, 2015.

[6] W. Afzal, T. Arab, T. Ullah, K. Teller, and K. J. Doshi, “Generalized lymphadenopathy as presenting feature of systemic lupus erythematosus: case report and review of the literature,” Journal of Clinical Medicine Research, vol. 8, no. 11, pp. 819–823, 2016.

[7] S. Giannouli, M. Voulgarelis, P. D. Ziakas et al., “Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment,” Annals of the Rheumatic Diseases, vol. 65, no. 2, pp. 144–148, 2006.

[8] W. L. Ng, C. M. Chu, A. K. L. Wu, V. C. C. Cheng, and K. Y. Yuen, “Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus,” QJM: An International Journal of Medicine, vol. 99, no. 1, pp. 37–47, 2006.

[9] M. Kuwana, J. Kaburaki, Y. Okazaki, H. Miyazaki, and Y. Ikeda, “Concise report: two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus,” Rheumatology, vol. 45, no. 7, pp. 851–854, 2006.

[10] F. Musio, E. M. Bohen, C. M. Yuan, and P. G. Welch, “Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus,” Seminars in Arthritis and Rheumatism, vol. 28, no. 1, pp. 1–19, 1998.

[11] I. A. Al-Homood, “Thrombosis in systemic lupus erythematosus: a review article,” ISRN Rheumatology, vol. 2012, Article ID 428269, 6 pages, 2012.

[12] J. C. Crispín, M. Öukka, G. Bayliss et al., “Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys,” The Journal of Immunology, vol. 181, no. 12, pp. 8761–8766, 2008.

[13] J. Bourré-Tessier, T. Huynh, A. Clarke et al., “Features associated with cardiac abnormalities in systemic lupus erythematosus,” Lupus, vol. 20, no. 14, pp. 1518–1525, 2011.

[14] C. A. Roldan, B. K. Shively, and M. H. Crawford, “An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus,” New England Journal of Medicine, vol. 335, no. 19, p. 1424, 1996.

[15] C. A. Roldan, W. L. Sibbitt Jr., C. R. Qualls et al., “Libman-Sacks endocarditis and embolic cerebrovascular disease,” JACC: Cardiovascular Imaging, vol. 6, no. 9, p. 973, 2013.

[16] M. Holmqvist, J. F. Simard, K. Asplund, and E. V. Arkema, “Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies,” RMD Open, vol. 1, no. 1, Article ID e000168, 2015.

[17] S. Y. Lim, E. H. Bae, K. D. Han et al., “Systemic lupus erythematosus is a risk factor for atrial fibrillation: a nationwide, population-based study,” Clinical and Experimental Rheumatology, vol. 37, no. 6, pp. 1019–1025, 2019.

[18] M. Petri, A. M. Orbai, G. S. Alarcón et al., “Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus,” Arthritis & Rheumatology, vol. 64, no. 8, pp. 2677–2686, 2012.

[19] C. D. Smith, C. Marino, and N. F. Rothfield, “The clinical utility of the lupus band test,” Arthritis & Rheumatism, vol. 27, no. 4, pp. 382–387, 1984.

[20] M. M. Ward, “Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996–2004,” The Journal of Rheumatology, vol. 36, no. 1, pp. 63–67, 2009.

[21] C. N. Kotton, “CMV: prevention, diagnosis and therapy,” American Journal of Transplantation, vol. 13, no. s3, p. 24, 2013.